Patents Assigned to Merck
  • PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION
    Publication number: 20240228535
    Abstract: The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 20, 2023
    Publication date: July 11, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: John J. Acton, III, Mayuri Gupta, Michael J. Kelly, III, Franca-Maria Klingler, Mark Eric Layton, John A. McCauley, Gregori J. Morriello, Christopher Charles Nawrat, Craig A. Parish, Anthony J. Roecker, Manuel de Lera Ruiz, Jing Su, Valerie W. Shurtleff, Quang T. Truong
  • EGFR TARGETING FC ANTIGEN BINDING FRAGMENT-DRUG CONJUGATES
    Publication number: 20240226319
    Abstract: The invention relates to EGFR targeting Fc antigen binding fragment-drug conjugates (EGFR Fcab-drug conjugates) and the use of the EGFR Fcab-drug conjugates of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such EGFR Fcab-drug conjugates. Further, the invention relates to EGFR Fcab-label conjugates and diagnostic compositions containing such EGFR Fcab-label conjugates.
    Type: Application
    Filed: May 23, 2022
    Publication date: July 11, 2024
    Applicant: MERCK PATENT GMBH
    Inventors: Sebastian JAEGER, Christian SCHROETER
  • BLOW-FILL SEALING METHOD FOR FILLING AND PACKAGING
    Publication number: 20240226439
    Abstract: A method of controlling a temperature of a biopharmaceutical product during blow-fill sealing, includes developing a model based on heat transfer mechanisms that incorporates the effects of the blow-fill sealing on the biopharmaceutical product, providing a parison to a blow-fill sealing machine for accepting the biopharmaceutical product during the blow-fill sealing, predicting a temperature of at least one the biopharmaceutical product, the parison, and a component of the blow-fill sealing machine at a stage in the blow-fill sealing, and adjusting a parameter of the blow-fill sealing machine to reduce damage to the biopharmaceutical product.
    Type: Application
    Filed: October 11, 2023
    Publication date: July 11, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Carl Chew, Matthew H. Flamm, Jeremy A. Haddock, Rikhabh Jain, Atul Karande, Brit L. Rudeen
  • RIPK1 INHIBITORS AND METHODS OF USE
    Publication number: 20240228506
    Abstract: Described herein are compounds of Formula II, or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: April 21, 2022
    Publication date: July 11, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Erin F. DiMauro, Xavier Fradera, Peter H. Fuller, Min Lu, Joey L. Methot, Matthew J. Mitcheltree, Andrew J. Musacchio, Phieng Siliphaivanh, Jing Su
  • COMBINATION THERAPIES FOR TREATING CANCER
    Publication number: 20240226082
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 11, 2024
    Applicants: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
  • LIQUID-CRYSTALLINE MEDIUM
    Publication number: 20240228877
    Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular energy saving LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type. The media have an improved long-term stability against UV radiation and elevated temperatures.
    Type: Application
    Filed: December 6, 2023
    Publication date: July 11, 2024
    Applicant: Merck Patent GmbH
    Inventors: Yeon-Jeong Han, Dong-Hyun Kim, Sang-Hyun Park, Sun-Mi Park, Heui-Seok Jin
  • Materials for organic electroluminescent devices
    Patent number: 12035625
    Abstract: The invention relates to compounds of formula (1) which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds. X is, identically or differently in each occurrence, CR or N, or two adjacent X stand for a group of the following formula (2), wherein the dashed bonds mark the bonding of said group in formula (1), with the stipulation that the compound of formula (1) contains one or two groups of formula (2); X1 is, identically or differently in each occurrence, CR or N; Y is, identically or differently in each occurrence, CR or N; Z1, Z2, Z3 are, identically or differently in each occurrence, O, S, N—Ar or CR2.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: July 9, 2024
    Assignee: Merck Patent GmbH
    Inventors: Amir Parham, Christian Eickhoff, Rouven Linge, Jens Kaiser, Amel Mekic
  • N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
    Patent number: 12030872
    Abstract: The present invention is directed to substituted certain N-heteroaryl indazole derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: July 9, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Vladimir Simov, William P. Kaplan, John J. Acton, III, Michael J. Ardolino, Joanna L Chen, Peter H. Fuller, Hakan Gunaydin, Derun Li, Ping Liu, Kaitlyn Marie Logan, Joey Methot, Gregori J. Morriello, Santhosh F. Neelamkavil, Luis Torres, Xin Yan, Hua Zhou
  • Polymerisable LC medium and polymer film with flat optical dispersion
    Patent number: 12031079
    Abstract: The invention relates to a polymerisable LC medium with flat, negative or positive optical dispersion, a polymer film with flat, negative or positive optical dispersion obtainable from such a material, and the use of the polymerisable LC medium and polymer film in optical, electro optical, electronic, semiconducting or luminescent components or devices.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: July 9, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Eduardo Beltran Gracia, Kevin Adlem, Naomi Weare, Hassan Norouzi-Arasi
  • Method for producing an electronic component which includes a self-assembled monolayer
    Patent number: 12035546
    Abstract: The invention relates to a process for the production of an electronic component comprising a self-assembled monolayer (SAM) using compounds of the formula I R1-(A1-Z1)r—(B1)n—(Z2-A2)s-Sp-G??(I) in which the groups occurring have the meanings defined in Claim 1; the present invention furthermore relates to the use of the components in electronic switching elements and to compounds for the production of the SAM.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: July 9, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Peer Kirsch, Sebastian Resch, Henning Seim, Marc Tornow, Takuya Kamiyama, Gerd-Volker Roeschenthaler, Romana Pajkert, Jacob Woodruff, Charith Nanayakkara
  • System and method for controlling the state of two or more liquid-crystal-based switchable elements
    Patent number: 12031378
    Abstract: A method for controlling the state of two or more liquid crystal-based switchable elements is proposed, wherein the switchable elements are configured as smart windows and/or as switchable subunits of smart windows, wherein in a first step a), at least two keyframes are defined, wherein each keyframe comprises setting values defining the intended state of a group of switchable elements. In a subsequent step b), a display frame is computed, wherein the display frame comprises setting values for the state of the group of switchable elements based on at least one of the defined keyframes. In a subsequent step c), the state of each of the switchable elements of the group of switchable elements is set as defined by the setting values of the computed display frame. Also, a master controller for use with the method, and a system implementing the method.
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: July 9, 2024
    Assignee: Merck Patent GmbH
    Inventors: Ties de Jong, Heiko Christ, Jasper van den Muijsenberg, Jens Osterodt, Abraham Karel Riemens
  • Compounds with diazadibenzofurane or diazadibenzothiophene structures
    Patent number: 12030890
    Abstract: The present invention describes diazadibenzofuran or diazadibenzothiophene derivatives substituted by carbazole, fluorene, phenanthrene, benzofuran and/or benzothiophene groups, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: July 9, 2024
    Assignee: Merck Patent GmbH
    Inventors: Amir Parham, Thomas Eberle, Anja Jatsch, Tobias Grossmann, Jonas Kroeber
  • Switching layer for use in an optical switching element
    Patent number: 12031078
    Abstract: The present invention relates to a switching layer based on a liquid-crystalline mixture for use in an optical switching element. The invention also encompasses a switching element comprising the switching layer and a window element containing the switching element. The liquid crystalline mixture comprises a low-molecular liquid crystal component, a polymer component and a self-alignment additive for vertical alignment.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 9, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Dong-Mee Song, Jung-Min Lee, Yong-Hyun Choi, Yong-Kuk Yun
  • NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS
    Publication number: 20240218009
    Abstract: Novel forms of 2-amino-9-[(2R,5R,7R,8S,10R,12aR, 14R,15S,15aR,16R)-14-(6-amino-9H-purin-9-yl)-15,16-difluoro-2,10-dihydroxy-2,10-disulfidooctahydro-12H-5,8-methanofuro[3,2-1][1,3,6,9,11,2,10]pentaoxadiphospha-cyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one, which include adducts of 2-amino-9-[(2R,5R,7R,8S,10R,12aR, 14R,15S,15aR,16R)-14-(6-amino-9H-purin-9-yl)-15,16-difluoro-2,10-dihydroxy-2,10-disulfidooctahydro-12H-5,8-methanofuro[3,2-1][1,3,6,9,11,2,10]pentaoxadiphospha-cyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one and L-histidine, may be useful as inductors of type I interferon production, specifically as STING active agents.
    Type: Application
    Filed: April 18, 2022
    Publication date: July 4, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephanus Axnanda, Andrew Patrick Jude Brunskill, Erin N. Guidry, Eric A. Kemp, Courtney K. Maguire, Mikhail Reibarkh, Matthew S. Winston
  • RFID label
    Patent number: 12026568
    Abstract: The invention concerns a RFID label for marking containers or equipment, preferably in a laboratory environment and including in particular cylindrical bottles, vials, syringes, etc., by adhering the RFID layer to a surface thereof. The RFID label has a flat flexible support material base (11), at least one RFID microelectronic device (5c) included in the flat support material base (11), and at least one antenna (5a,5b) connected with the at least one RFID microelectronic device (5c) and included in the flat support material base (11). The flat support material base (11) has a number of predefined cuts (8) distributed about its outer periphery and/or the at least one RFID microelectronic device (5c) includes a tamper detection function and a conductive loop (5d) connected with tamper detection function terminals of the RFID microelectronic device (5c) is included in the flat support material base (11).
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: July 2, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Christian-Hubertus Kuechenthal, Roja Azees, Dan Kvelstad, Sven Erfurth
  • Isomerically pure F-labelled tetrahydrofolates
    Patent number: 12023390
    Abstract: The present invention is directed towards isomerically pure 18F-labelled (6S)- or (6R)-5-methyltetrahydrofolate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18F-labelled N-heterocycle, for use in diagnostic imaging of a cell or population of cells expressing a folate-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: July 2, 2024
    Assignee: Merck Patent GmbH
    Inventors: Rudolf Moser, Viola Groehn, Cristina Mueller, Roger Schibli, Simon Ametamey, Silvan Boss
  • OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT
    Publication number: 20240208958
    Abstract: The present invention relates to the oxazolidinone compound of Formula (I): and pharmaceutically acceptable salts thereof. The present invention also relates to compositions containing the compound of Formula (I). The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering a therapeutically effective amount of Formula (I) and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
    Type: Application
    Filed: March 20, 2021
    Publication date: June 27, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Brendan M. CROWLEY, Philippe NANTERMET, David B. OLSEN, Takao SUZUKI, Lihu YANG, Lanying YOU
  • EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20240208987
    Abstract: The present disclosure is directed to linker-payloads, and salts (including pharmaceutically acceptable salts), solvates, or stereoisomers thereof, comprising a structure of formula I: The disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds, intermediates thereof, and compositions in the prevention or treatment of cancers and/or tumors.
    Type: Application
    Filed: October 23, 2023
    Publication date: June 27, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Vlad Bacauanu, Manoj B. Charati, Sijie Chen, Rebecca Elizabeth Johnson, Simon B. Lang, Christian L. Morales, Ryan Quiroz, W. Michael Seganish, Nancy Zepeda
  • PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240208986
    Abstract: Described herein are compounds of Formula I: (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 27, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Joanna L. Chen, Erin F. DiMauro, Kevin D. Dykstra, Xavier Fradera, Peter H. Fuller, Charles A. Lesburg, Min Lu, Joey L. Methot, Matthew J. Mitcheltree, Jing Su
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240208994
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: April 18, 2022
    Publication date: June 27, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Alan C. Cheng, Ying-Duo Gao, Song Yang, Mihir Mandal, Jiafang He, Jovan Alexander Lopez, Maoqun Tian